SUN PHARMA ADVANCED RESEARCH COMPANY
|
|
BOM : 532872     NSE : SPARC     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Jun 11,2025 |
Price(EOD): ₹ 165.85
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Business Support |
MCap: ₹ 5,381.83 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SUN PHARMA ADVANCED RESEARCH COMPANY | 2.3% | 10.6% | -25% |
SYNGENE INTERNATIONAL | 2.4% | 5.4% | -3.9% |
SAGILITY INDIA | 2.8% | -10.8% | NA |
LATENT VIEW ANALYTICS | 1.3% | -1.8% | -16.1% |
JUST DIAL | 2.5% | -1.9% | -4.1% |
AWFIS SPACE SOLUTIONS | -2.4% | 7.4% | 69.5% |
MEDI ASSIST HEALTHCARE SERVICES | 1.9% | 6.6% | -1.3% |
JAYKAY ENTERPRISES | NA | -2.6% | 142.2% |
ECOS (INDIA) MOBILITY & HOSPITALITY | 10% | 52.6% | NA |
FUNDAMENTAL ANALYSIS OF SUN PHARMA ADVANCED RESEARCH COMPANY
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SUN PHARMA ADVANCED RESEARCH COMPANY
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
-15.71
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -342.51 Cr
[Latest Qtr - Mar2025 - Consolidated Results ] -24.81
P/B Calculated based on Book Value of Rs -216.95 Cr
[Latest Year - Mar2025 - Consolidated Results ] 74.99
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 71.77 Cr
[Latest Qtr - Mar2025 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA 109% 119% |
SHARE PRICE MOMENTUM OF SUN PHARMA ADVANCED RESEARCH COMPANY
SUN PHARMA ADVANCED RESEARCH COMPANY vs SENSEX
DEBT OF SUN PHARMA ADVANCED RESEARCH COMPANY
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.38 0 -0.37 - |
0.37 0 - 0.12 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SUN PHARMA ADVANCED RESEARCH COMPANY
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2025 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SUN PHARMA ADVANCED RESEARCH COMPANY
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
82.36% 27.83% 23.63% 24.83% |
64.19% 49.75% 42.44% 43.5% |
QtrlyTrend |
8 | |
Latest Qtr: Mar2025 | ||
Quarterly Result Analysis → |
SUN PHARMA ADVANCED RESEARCH COMPANY related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
BSE ALLCAP | 6.4% | 8.9% | 7.5% |
BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
BSE HEALTHCARE | 3.1% | 5.8% | 23.7% |
BSE 250 SMALLCAP INDEX | 2.8% | 11% | 13.4% |
BSE SMALLCAP | 2.7% | 11.5% | 17.3% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY MICROCAP 250 | 3.1% | 11.9% | 20.6% |
NIFTY TOTAL MARKET | 2.4% | 4% | 11.2% |
You may also like the below Video Courses
FAQ about SUN PHARMA ADVANCED RESEARCH COMPANY
Is SUN PHARMA ADVANCED RESEARCH COMPANY good for long term investment?
As on Jun 11,2025, the Fundamentals of SUN PHARMA ADVANCED RESEARCH COMPANY look Poor and hence it may not be good for long term investment ! See Financial Performance of SUN PHARMA ADVANCED RESEARCH COMPANY . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SUN PHARMA ADVANCED RESEARCH COMPANY UnderValued or OverValued?
As on Jun 11,2025, SUN PHARMA ADVANCED RESEARCH COMPANY is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SUN PHARMA ADVANCED RESEARCH COMPANY ?
As on Jun 11,2025, the Intrinsic Value of SUN PHARMA ADVANCED RESEARCH COMPANY is Rs. 77.46 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. -931.70
Fair Value [Median EV / Sales Model] : Rs. 79.28
Fair Value [Median Price / Sales Model] : Rs. 75.64
Estimated Median Fair Value of SUN PHARMA ADVANCED RESEARCH COMPANY : Rs. 77.46
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.